Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (plasma cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: idecabtagene vicleucel, belantamab mafodotin, ciltacabtagene autoleucel +2 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9287
Sealed predictions
- TNFRSF17 in dopamine neurons, braak+0.42 (p 0.262) → +0.48 (p 0.195)receipt 9294
Swarm cases
receipt 9294: TNFRSF17 in dopamine neurons, braak
- power
- full sample +0.43 (p 0.074, n 18), 95% CI -0.04 to +0.75. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.46 (p 0.056, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.47 (p 0.050, n 18). not the mix.
- skeptic
- leave-one-out range +0.36 to +0.53, sign flips 0; without severely affected donors +0.43 (p 0.074, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TNFRSF17 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts